TCGA-93-A4JN-01A-11R-A24X-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- INTERFERON_GAMMA_RESPONSE+0.370
- TGF_BETA_SIGNALING+0.320
- MITOTIC_SPINDLE+0.260
- UV_RESPONSE_DN+0.250
- APICAL_JUNCTION+0.200
- MYOGENESIS+0.190
- WNT_BETA_CATENIN_SIGNALING+0.190
- NOTCH_SIGNALING+0.180
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.170
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.550
- PANCREAS_BETA_CELLS-0.520
- MTORC1_SIGNALING-0.480
- MYC_TARGETS_V1-0.470
- MYC_TARGETS_V2-0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- CHOLESTEROL_HOMEOSTASIS-0.380
- FATTY_ACID_METABOLISM-0.380
- PROTEIN_SECRETION-0.350
- ADIPOGENESIS-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR15030864 | — | — | 0.826 |
| 2 | SRR35579838 | — | D | 0.803 |
| 3 | s_150203_3a | EPN | Supratentorial EPN | 0.794 |
| 4 | SRR5088847 | — | — | 0.789 |
| 5 | TCGA-BH-A0B5-01A-11R-A12P-07 | — | A | 0.784 |
| 6 | AUR-AFEA-TTP1-A-1-0-R-A741-41 | — | D | 0.780 |
| 7 | SRR6013599 | — | cohortMD2 | 0.780 |
| 8 | AUR-AFE5-TTM4-A-1-1-R-A742-41 | — | D | 0.775 |
| 9 | BSR_12_0175_A5_S64 | — | D | 0.774 |
| 10 | SRR35579832 | — | A | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.060 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.060 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.060 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.040 | Inavolisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |